PSMA-617 manufacturers
- Vipivotide tetraxetan
-
- $193.00 / 1mg
-
2024-11-19
- CAS:1702967-37-0
- Min. Order:
- Purity: 98.45%
- Supply Ability: 10g
- Vipivotide tetraxetan
-
- $193.00 / 1mg
-
2024-11-19
- CAS:1702967-37-0
- Min. Order:
- Purity: 98.45%
- Supply Ability: 10g
- PSMA-617
-
- $0.00 / 1GRAM
-
2024-09-25
- CAS:1702967-37-0
- Min. Order: 1GRAM
- Purity: 99%
- Supply Ability: 20 TONS
|
| | PSMA-617 Basic information |
| Product Name: | PSMA-617 | | Synonyms: | PSMA-617;Vipivotide tetraxetan;L-Lysine, N2-[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]-N6-[3-(2-naphthalenyl)-N-[[trans-4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]methyl]cyclohexyl]carbonyl]-L-alanyl]-;Vipivotide tetraxetan (PSMA-617);PSMA617,Vipivotide tetraxetan;Actinium-225-PSMA-Trillium(BAY3563254);(((S)-1-Carboxy-5-((S)-3-(naphthalen-2-yl)-2-((1r,4S)-4-((2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)methyl)cyclohexane-1-carboxamido)propanamido)pentyl)carbamoyl)-L-glutamic acid;(2S)-2-({[(1S)-1-carboxy-5-[(2S)-3-(naphthalen-2-yl)-2-{[(1s,4s)-4-[(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)methyl]cyclohexyl]formamido}propanamido]pentyl]carbamoyl | | CAS: | 1702967-37-0 | | MF: | C49H71N9O16 | | MW: | 1042.14 | | EINECS: | | | Product Categories: | ADC | | Mol File: | 1702967-37-0.mol |  |
| | PSMA-617 Chemical Properties |
| Boiling point | 1371.9±65.0 °C(Predicted) | | density | 1.322±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Water:150.0(Max Conc. mg/mL);100.13(Max Conc. mM)
DMSO:125.0(Max Conc. mg/mL);83.43(Max Conc. mM) | | form | Solid | | pka | 1.83±0.10(Predicted) | | color | White to off-white |
| | PSMA-617 Usage And Synthesis |
| Uses | PSMA-617 has been used in prostate cancer research, and is a promising prostate-specific membrane antigen-targeted theranostic agent. | | in vivo | Organ distribution with 68Ga-labeled Vipivotide tetraxetan (PSMA-617) after 1 h (n=3) reveals a high specific uptake in LNCaP tumors and in the kidneys. The high uptake in the kidneys is nearly completely blocked by coinjection of 2 mg of 2-PMPA per kilogram. Other organs such as the liver, lung, and spleen show rather low uptake and no blocking effect, with the exception of the spleen. Tumor-to-background ratios are 7.8 (tumor to blood) and 17.1 (tumor to muscle) at 1 h after injection. As compared with the 68Ga-labeled version, the organ distribution with 177Lu-labeled Vipivotide tetraxetan (PSMA-617) (n=3) show a similar uptake in the LNCaP tumors and in the kidneys. The liver uptake is found to be statistically different. Tumor-to-background ratios determined 1 h after injection show slightly higher values (tumor to blood, 22.1; tumor to muscle, 25.6) than previous organ distribution with 68Ga-labeled Vipivotide tetraxetan (PSMA-617)[1]. | | IC 50 | Traditional Cytotoxic Agents |
| | PSMA-617 Preparation Products And Raw materials |
|